Analysts expect bluebird bio Inc (NASDAQ:BLUE) to post earnings of ($3.03) per share for the current fiscal quarter, according to Zacks. Nine analysts have provided estimates for bluebird bio’s earnings, with the highest EPS estimate coming in at ($2.72) and the lowest estimate coming in at ($3.35). bluebird bio reported earnings per share of ($2.91) in the same quarter last year, which indicates a negative year-over-year growth rate of 4.1%. The business is expected to report its next earnings report on Thursday, August 1st.
According to Zacks, analysts expect that bluebird bio will report full-year earnings of ($12.25) per share for the current fiscal year, with EPS estimates ranging from ($13.80) to ($10.91). For the next fiscal year, analysts expect that the business will report earnings of ($11.57) per share, with EPS estimates ranging from ($13.72) to ($7.16). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow bluebird bio.
bluebird bio (NASDAQ:BLUE) last issued its earnings results on Thursday, May 2nd. The biotechnology company reported ($2.99) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($2.79) by ($0.20). bluebird bio had a negative net margin of 1,184.01% and a negative return on equity of 34.01%. The company had revenue of $12.47 million during the quarter, compared to analysts’ expectations of $15.49 million. During the same period last year, the business posted ($2.31) earnings per share. The company’s quarterly revenue was down 21.9% on a year-over-year basis.
Shares of BLUE opened at $119.92 on Wednesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 9.31 and a current ratio of 9.31. The stock’s 50 day simple moving average is $123.77. bluebird bio has a 1-year low of $87.49 and a 1-year high of $183.60. The stock has a market cap of $6.50 billion, a PE ratio of -11.23 and a beta of 2.51.
In other news, insider Jeffrey T. Walsh sold 1,500 shares of the business’s stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price of $156.65, for a total transaction of $234,975.00. Following the sale, the insider now owns 42,421 shares in the company, valued at $6,645,249.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Philip D. Gregory sold 1,800 shares of the business’s stock in a transaction that occurred on Wednesday, June 5th. The shares were sold at an average price of $128.60, for a total transaction of $231,480.00. Following the sale, the insider now owns 32,192 shares in the company, valued at approximately $4,139,891.20. The disclosure for this sale can be found here. Insiders have sold 19,020 shares of company stock worth $2,754,837 in the last 90 days. 3.00% of the stock is owned by company insiders.
Several hedge funds have recently added to or reduced their stakes in the company. Bank of Montreal Can grew its position in bluebird bio by 0.3% during the first quarter. Bank of Montreal Can now owns 42,169 shares of the biotechnology company’s stock valued at $6,634,000 after purchasing an additional 114 shares in the last quarter. Clearbridge Investments LLC raised its stake in bluebird bio by 18.2% during the 1st quarter. Clearbridge Investments LLC now owns 839 shares of the biotechnology company’s stock valued at $132,000 after purchasing an additional 129 shares during the last quarter. Woodstock Corp raised its stake in bluebird bio by 2.2% during the 1st quarter. Woodstock Corp now owns 6,408 shares of the biotechnology company’s stock valued at $1,008,000 after purchasing an additional 137 shares during the last quarter. Advisor Group Inc. raised its stake in bluebird bio by 15.5% during the 4th quarter. Advisor Group Inc. now owns 1,256 shares of the biotechnology company’s stock valued at $124,000 after purchasing an additional 169 shares during the last quarter. Finally, Icon Wealth Partners LLC acquired a new position in bluebird bio during the 1st quarter valued at $31,000.
About bluebird bio
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.